Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-DA-EPOCH-21 vs R-mNHL-BFM-90 +/- auto-SCT in DLBCL
NCT02842931Phase 3Unknown
- Sponsor
- National Medical Research Center for Hematology
- Start
- Feb 2015
- Primary completion
- Feb 2020
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of R-EPOCH and R-mNHL-BFM-90 in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by National Medical Research Center for Hematology. Primary endpoint: Complete Response at 168 days. Status: unknown.
02
Drugs
R-EPOCHR-mNHL-BFM-90
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02842931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842931.